BioXcel Therapeutics is trading 74.65% down now at $0.18 after the company and subsidiaries filed for Chapter 11 protection on August 27, 2026.
- Proposed sale of substantially all assets to Teva Pharmaceuticals, the stalking-horse bidder in a court-supervised auction.
- Reuters confirmed the filing; reports cite Teva’s $57.5 million upfront offer plus potential milestone payments.
- The process sharply increases uncertainty for existing shareholders; shares closed at $0.72 on August 27 before collapsing at the August 28 open.